Breast Cancer

Boehringer Ingelheim announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform.  NBE-T more

After cancer surgery, the crucial question is: Are there possibly cancer cells left behind that can continue to grow, or has the entire tumor actually been removed? To find out, the tumor is examined by pathologists. Until now, thin sections were made which were then analyzed under a microscope. A n more

Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, w more

by Monika Lesicka, Ewa Jabłońska, Edyta Wieczorek, Barbara Seroczyńska, Anna Siekierzycka, Jarosław Skokowski, Leszek Kalinowski, Wojciech Wąsowicz, Edyta Reszka Breast cancer has a multifactorial etiology. One of the supposed and novel mechanisms is an alteration of circadian gene expression. Ci more

The adult mammary gland is a bilayered branching epithelial structure consisting of an outer layer of basal cells and an inner layer of luminal cells. The neonatal structure expands rapidly during puberty and then undergoes cyclic growth in response to the changing hormonal stimuli (progesterone and more

Marine Drugs, Vol. 16, Pages 220: Cyanopeptolins with Trypsin and Chymotrypsin Inhibitory Activity from the Cyanobacterium Nostoc edaphicum CCNP1411 Marine Drugs doi: 10.3390/md16070220 Authors: Hanna Mazur-Marzec Anna Fidor Marta Cegłowska Ewa Wieczerzak Magdalena Kropidłowska Ma more